Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies. 

	The panelists in this roundtable discussion included: John Allinson, head of biomarker strategy, drug development services at LGC; Martha S. Rook, head of novel therapies, process solutions, MilliporeSigma; Joe Codamo, general manager, Patheon; Brian Hampson, Vice-President, Global Manufacturing Sciences and Technology, PCT, a Caladrius Company; Stephen Gacheru, Executive Director–Biopharmaceutical Product Development, PPD Laboratories; Bruce Stauffer, Executive Director–Immunochemistry Department, PPD Laboratories; and Mark Rogers, VP USA–Life Science, SGS.

Articles

Features

Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.

Contract Service Providers Gear Up to Develop Emerging Therapies

Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.

	Participants in this discussion included: Don Paul Kovarcik, technical marketing specialist, Ajinomoto Althea; Robert H. DeWit, president of MPI Research; John Allinson, head of biomarker strategy, drug development services at LGC; Michael Lehmann, president, global sales and marketing, Patheon; Brian Hampson, vice-president, global manufacturing sciences and technology, PCT, a Caladrius Company; Fiona Greer, global director, BioPharma Services Development–Life Sciences, SGS; and Peter Soelk, managing director, Vetter Pharma International.

Biopharma Service Providers Address a Full Plate of Challenges

The pharmaceutical supply chain faces many changes, and service providers have to accept changes in market demand and adapt to the circumstances accordingly. Experienced contract

	development and manufacturing organizations (CDMOs) can offer answers to the challenging supply chain and deliver high product quality.

Planning ahead is key to enabling a continuous and secure supply chain that adapts to changes in market demand.

Dealing with Pharmaceutical Supply-Chain Complexities

The right approach to thinking about drug-delivery options can help ensure success, especially when working with contract partners. BioPharm International asked 3M Drug Delivery Services team members Richard Beesley, global business development manager; Louise Righton, global marketing operations manager; and Ross Errington, sales manager, to share some best practices. 

For successful drug delivery partnerships, it’s important to take a long-term view, focus on simple designs, and address potential payer concerns up front.

Keeping it Simple: Collaborating for Success in Drug Delivery

New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China. To compete in this resource-intensive manufacturing process that requires large volume capacity and a technically trained labor force, it is logical pharmaceutical companies will turn to contract manufacturing in China to meet strategic sourcing requirements.

New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.

Regulatory Reform in China: Implications for Global Biopharmaceutical Companies

Quality considerations have always been vital to biotherapeutic developers and CMOs. Yet, in 2016, it seems that these considerations are taking on a new emphasis. One of the main industry trends seen this year-increased attention to continuous bioprocessing-is at least partly driven by the potential for improved product quality.

Biopharmaceutical manufacturers continue to put quality at the forefront of their relationships.

Biomanufacturers Demand Higher Quality Standards in 2016

Only half of new drugs make it past Phase III. Adopting best practices and collaborating more closely with contract research organizations can help ensure success.

Adopting best practices and collaborating more closely with contract research organizations can help drugs get past Phase III.

Preventing Phase III Failures

The biopharmaceutical outsourcing industry has been marked by investment in technology and facility upgrades, mergers, acquisitions, and development partnerships in 2016. This article details are some of the latest developments in the biopharmaceutical outsourcing market.

Biopharmaceutical contractors continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.

BioPharm International-06-15-2016